The 52-week price high and low points are important variables to concentrate on when assessing the current and prospective worth of a stock. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. Why Buy stock in Uber Technologies, Inc. (UBER)? The company’s shares have gained +205.26% over the past 6 months, with this year growth rate of -0.93%, compared to 14% for the industry. Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. Growth estimates for the current quarter are 29.4% and 31.6% for the next quarter. In the most recent purchasing and selling session, PDC Energy Inc. (PDCE)’s share price increased by 0.59 percent to ratify at $12.77. BOV News. The current EPS Growth rate for the company during the year is 0.50% and predicted to reach at 169.60% for the coming year. The 3-month trading volume is 718.07 Million shares. In a separate transaction which took place on 9/30/2020, the institutional investor, ENVESTNET ASSET MANAGEMENT, INC. bought 5.6 thousand shares of the company’s stock. PDC Energy Inc. (PDCE) shares reached a high of $13.01 and dropped to a low of $12.43 until finishing in the latest session at $12.57. The Williams Percent Range or Williams %R is a well-known specialized pointer made by Larry Williams to help recognize overbought and oversold circumstances. Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination Clinical study remains on track, initial data readout expected Q4 2020 SAN DIEGO , Sept. SAN DIEGO , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory, Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage, COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School ; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency, Phase 1, Nationally recognized leader in corporate life sciences transactions SAN DIEGO , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease, SAN DIEGO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory, Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate, Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference, Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences, Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate, Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health, Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study, Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update, Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer, Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020.
Google+. In another most recent transaction, which held on 9/30/2020, SIMPLEX TRADING LLC bought approximately 8.9 thousand shares of PDC Energy Inc. IA "Marketing Sentinel" seeks to provide the news and analytical information to both American and foreign audiences, events and events in the USA and all over the world reliably, objectively and promptly. The information agency "Marketing Sentinel" was established at the end of 2004.